CL2013000596A1 - Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf. - Google Patents

Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf.

Info

Publication number: CL2013000596A1
Authority: CL; Chile
Prior art keywords: vegf; composition; union; encodes; molecules
Prior art date: 2010-09-03

Application number

CL2013000596A

Other languages

English (en)

Inventor

Andreas Gschwind

Eric Borges

Joachim Boucneau

Tavernier Evelyn De

Joost Kolkman

Pascal Merchiers

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-03

Filing date

2013-03-01

Publication date

2014-02-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43530923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-01 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2014-02-14 Publication of CL2013000596A1 publication Critical patent/CL2013000596A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CL2013000596A 2010-09-03 2013-03-01 Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf. CL2013000596A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10175318		2010-09-03

Publications (1)

Publication Number	Publication Date
CL2013000596A1 true CL2013000596A1 (es)	2014-02-14

Family

ID=43530923

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000596A CL2013000596A1 (es)	2010-09-03	2013-03-01	Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf.

Country Status (17)

Country	Link
US (6)	US20120225081A1 (es)
EP (2)	EP2727939A3 (es)
JP (1)	JP5979504B2 (es)
KR (1)	KR101844875B1 (es)
CN (1)	CN103209995B (es)
AR (1)	AR082892A1 (es)
AU (1)	AU2011298281B2 (es)
BR (1)	BR112013005151A2 (es)
CA (1)	CA2808696C (es)
CL (1)	CL2013000596A1 (es)
EA (1)	EA029277B1 (es)
IL (1)	IL224800B (es)
MX (1)	MX353813B (es)
NZ (1)	NZ607394A (es)
PH (1)	PH12013500410B1 (es)
UY (1)	UY33588A (es)
WO (1)	WO2012028716A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9527925B2 (en) *	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
WO2014031856A1 (en) *	2012-08-23	2014-02-27	Onconthyreon Inc.	Combination therapy using pi3 kinase and braf inhibitors
KR101541478B1 (ko)	2013-05-31	2015-08-05	동아쏘시오홀딩스 주식회사	항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
US9388239B2 (en) *	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
AU2015376558B9 (en) *	2015-01-06	2021-07-01	Zhuhai Essex Bio-Pharmaceutical Co., Ltd.	Anti-VEGF antibody
US12128102B2 (en)	2016-03-08	2024-10-29	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
TW202302631A (zh) *	2016-03-08	2023-01-16	日商武田藥品工業股份有限公司	可誘導性結合蛋白和使用方法
KR102124286B1 (ko) *	2016-09-07	2020-06-18	삭신 라이프사이언스 피브이티 엘티디	Vegf에 대한 합성 항체 및 이들의 용도
WO2018175319A1 (en) *	2017-03-20	2018-09-27	Allergan, Inc.	Heavy chain only antibodies to vegf
WO2019051102A2 (en)	2017-09-08	2019-03-14	Maverick Therapeutics, Inc.	Constrained conditionally activated binding proteins
CA3130653A1 (en)	2018-03-09	2019-09-12	Valitor, Inc.	Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation
WO2020181140A1 (en)	2019-03-05	2020-09-10	Maverick Therapeutics, Inc.	Constrained conditionally activated binding proteins
CN110452297B (zh) *	2019-09-03	2020-04-14	上海洛启生物医药技术有限公司	抗vegf单域抗体及其应用
EP4192880A4 (en)	2020-08-05	2025-04-30	Synthekine, Inc.	IL10 receptor-binding molecules and methods of use
JP7819178B2 (ja)	2020-08-05	2026-02-24	シンセカインインコーポレイテッド	ＩＬ１０Ｒｂ結合分子および使用方法
US12540188B2 (en)	2020-08-05	2026-02-03	Synthekine, Inc.	IL10Rα/IL2Rγ synthetic cytokines
WO2022031890A1 (en)	2020-08-05	2022-02-10	Synthekine, Inc.	Ifngr2 binding molecules and methods of use
US20230365696A1 (en) *	2020-08-05	2023-11-16	Synthekine, Inc.	Ifngr1 binding molecules and methods of use
US12122839B2 (en)	2020-08-05	2024-10-22	Synthekine, Inc.	IFNGR binding synthetic cytokines and methods of use
CA3208389A1 (en) *	2021-02-19	2022-08-25	Ignacio ASIAL	Vegfa-binding molecules
EP4386004A4 (en) *	2021-08-13	2025-08-13	Innovent Biologics Suzhou Co Ltd	BISPECIFIC ANTI-VEGF A AND ANTI-VEGF C ANTIBODY AND ITS USE
CN115724968B (zh) *	2021-08-27	2023-08-08	三优生物医药(上海)有限公司	Vegf结合分子及其用途
CN113896805B (zh) *	2021-12-13	2022-02-25	上海惠盾因泰生物科技有限公司	一种vegf-crm197重组融合蛋白疫苗及其制备方法和应用
WO2024055995A1 (zh) *	2022-09-14	2024-03-21	寻济生物科技（北京）有限公司	一种抗vegfa融合蛋白及其制备方法和应用
JP2025534252A (ja) *	2022-09-14	2025-10-15	尋済生物科技（北京）有限公司	抗ｖｅｇｆａ抗体またはその抗原結合フラグメント、およびその使用
CN116284405B (zh) *	2023-03-15	2024-03-19	中国科学技术大学	靶向cd150蛋白的纳米抗体及其应用
CN118085081B (zh) *	2024-04-19	2024-06-21	云南大学	一种特异性结合vegf的纳米抗体及用途
US20260092125A1 (en) *	2024-09-06	2026-04-02	Eyebiotech Limited	Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1621554E (pt)	1992-08-21	2009-07-13	Univ Bruxelles	Imunoglobtainas desprovidas de cadeias leves
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6884879B1 (en) *	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
EP1274720A4 (en)	2000-04-12	2004-08-18	Human Genome Sciences Inc	FUSION PROTEINS CONTAINING ALBUMIN
CN101684158A (zh)	2001-01-17	2010-03-31	特鲁比昂药品公司	结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en)	2001-06-28	2008-09-11	Domantis Limited	Dual-specific ligand and its use
EP1463752A4 (en)	2001-12-21	2005-07-13	Human Genome Sciences Inc	ALBUM INFUSION PROTEINS
EP2284192A3 (en)	2002-11-08	2011-07-20	Ablynx N.V.	Camelidae antibodies for sublingual administration
EP1558647B1 (en)	2002-11-08	2015-06-10	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20050043220A1 (en) *	2002-11-08	2005-02-24	Guyer David R.	Methods and compositions for treating macular degeneration
JP4490290B2 (ja)	2002-12-31	2010-06-23	ネクターセラピューティクスアラバマ，コーポレイション	加水分解安定性マレイミド末端ポリマー
SI1639011T1 (sl)	2003-06-30	2009-04-30	Domantis Ltd	Pegilirana protitelesa z enojno domeno (dAb)
PT1687338E (pt)	2003-11-07	2011-01-20	Ablynx Nv	Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US20050284249A1 (en)	2004-06-29	2005-12-29	Arnone David F	Worm type gear mover assembly
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2006249144B2 (en)	2005-05-18	2011-11-17	Ablynx Nv	Improved NanobodiesTM against Tumor Necrosis Factor-alpha
WO2007143689A2 (en)	2006-06-06	2007-12-13	Genentech, Inc.	Compositions and methods for modulating vascular development
CA2666599A1 (en)	2006-08-18	2008-02-21	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2666974A1 (en)	2006-10-20	2008-11-06	Schering Corporation	Fully human anti-vegf antibodies and methods of using
CN101663319A (zh) *	2007-02-21	2010-03-03	埃博灵克斯股份有限公司	针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
US8216571B2 (en) *	2007-10-22	2012-07-10	Schering Corporation	Fully human anti-VEGF antibodies and methods of using
WO2009095489A2 (en)	2008-02-01	2009-08-06	Ablynx N.V.	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2717015A1 (en)	2008-03-05	2009-09-11	Ablynx Nv	Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2010124009A2 (en) *	2009-04-21	2010-10-28	Schering Corporation	Fully human anti-vegf antibodies and methods of using
UY32920A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US9527925B2 (en) *	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2

2011
- 2011-09-01 US US13/223,563 patent/US20120225081A1/en not_active Abandoned
- 2011-09-02 CA CA2808696A patent/CA2808696C/en active Active
- 2011-09-02 BR BR112013005151-5A patent/BR112013005151A2/pt not_active Application Discontinuation
- 2011-09-02 MX MX2013002379A patent/MX353813B/es active IP Right Grant
- 2011-09-02 UY UY0001033588A patent/UY33588A/es unknown
- 2011-09-02 KR KR1020137008330A patent/KR101844875B1/ko not_active Expired - Fee Related
- 2011-09-02 EA EA201300311A patent/EA029277B1/ru not_active IP Right Cessation
- 2011-09-02 AR ARP110103226A patent/AR082892A1/es not_active Application Discontinuation
- 2011-09-02 AU AU2011298281A patent/AU2011298281B2/en not_active Ceased
- 2011-09-02 PH PH1/2013/500410A patent/PH12013500410B1/en unknown
- 2011-09-02 CN CN201180052278.8A patent/CN103209995B/zh active Active
- 2011-09-02 JP JP2013526488A patent/JP5979504B2/ja not_active Expired - Fee Related
- 2011-09-02 EP EP13190391.6A patent/EP2727939A3/en not_active Withdrawn
- 2011-09-02 EP EP11749454.2A patent/EP2611830A1/en not_active Withdrawn
- 2011-09-02 WO PCT/EP2011/065199 patent/WO2012028716A1/en not_active Ceased
- 2011-09-02 NZ NZ607394A patent/NZ607394A/en not_active IP Right Cessation
2013
- 2013-02-19 IL IL224800A patent/IL224800B/en active IP Right Grant
- 2013-03-01 CL CL2013000596A patent/CL2013000596A1/es unknown
2015
- 2015-12-18 US US14/974,343 patent/US20160200806A1/en not_active Abandoned
2017
- 2017-12-05 US US15/831,754 patent/US20180201671A1/en not_active Abandoned
2020
- 2020-06-17 US US16/903,888 patent/US20200308267A1/en not_active Abandoned
2022
- 2022-06-21 US US17/844,812 patent/US20220363744A1/en not_active Abandoned
2024
- 2024-01-11 US US18/409,969 patent/US20240141030A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL224800B (en)	2020-03-31
NZ607394A (en)	2014-12-24
CA2808696A1 (en)	2012-03-08
US20160200806A1 (en)	2016-07-14
EA201300311A1 (ru)	2013-08-30
US20200308267A1 (en)	2020-10-01
JP2013541939A (ja)	2013-11-21
UY33588A (es)	2012-03-30
EA029277B1 (ru)	2018-03-30
EP2727939A3 (en)	2014-05-21
US20240141030A1 (en)	2024-05-02
US20120225081A1 (en)	2012-09-06
MX353813B (es)	2018-01-31
AU2011298281B2 (en)	2015-02-05
PH12013500410B1 (en)	2022-02-11
EP2611830A1 (en)	2013-07-10
CN103209995B (zh)	2015-11-25
EP2727939A2 (en)	2014-05-07
CA2808696C (en)	2016-12-20
BR112013005151A2 (pt)	2020-08-04
KR20130101045A (ko)	2013-09-12
AU2011298281A1 (en)	2013-03-14
US20220363744A1 (en)	2022-11-17
KR101844875B1 (ko)	2018-04-03
JP5979504B2 (ja)	2016-08-24
MX2013002379A (es)	2013-05-09
PH12013500410A1 (en)	2013-04-15
WO2012028716A1 (en)	2012-03-08
CN103209995A (zh)	2013-07-17
US20180201671A1 (en)	2018-07-19
AR082892A1 (es)	2013-01-16

Publication	Publication Date	Title
HUS2300027I1 (hu)	2023-12-28	BCMA (CD269/TNFRSF17)-kötõ fehérjék
CL2014000631A1 (es)	2014-09-26	Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2009000379A1 (es)	2012-02-24	Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CL2014002072A1 (es)	2015-01-23	Polipéptidos de unión a cx3cr1; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo contiene; metodo de elaboracion del peptido; usos del peptido; kit que contiene el peptido.
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2013000669A1 (es)	2014-02-14	Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie.
CL2015000094A1 (es)	2015-06-19	Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
EP3311802C0 (en)	2023-11-01	PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES
BR112015003570A2 (pt)	2018-05-22	composições de cimento ou de argamassa multi-uso para aplicações em construção.
BR112013011705A2 (pt)	2018-03-13	antígenos consensuais de próstata, molécula de ácido nucleico que os codificam e vacina e usos que os compreendem
BR112014012681A2 (pt)	2017-06-13	polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica
CL2013001947A1 (es)	2014-05-23	Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
DK2421879T3 (da)	2013-11-25	Nye 7-deazapurinnukleotider til terapeutiske anvendelser
EP2654736A4 (en)	2015-04-22	NOVEL PHARMACEUTICAL COMPOSITION
CL2013001290A1 (es)	2013-11-15	Anticuerpo aislado, o su fragmento, que se une a beta secretasa (bace1); acido nucleico que codifica el anticuerpo; celula huesped que comprende el acido nucleico; metodo para producir un anticuerpo; inmunoconjugado que comprende el anticuerpo; formulacion farmaceutica; uso del anticuerpo para tratar enfermedad o trastorno neurológico.
UY33588A (es)	2012-03-30	Moleculas de union a vegf
CL2012001143A1 (es)	2012-10-05	Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios.
EP2702989A4 (en)	2014-12-31	STABLE PHARMACEUTICAL COMPOSITION
EP2642979A4 (en)	2014-09-17	PHARMACEUTICAL COMPOSITION
BR112012001486A2 (pt)	2016-03-15	composição espumante para gerar indicações temporárias
EP2681198A4 (en)	2014-09-03	NEW LITTLE MOLECULES AS THERAPIES
CL2014003535A1 (es)	2015-05-08	Compuestos derivados de fenoxietil piperidina; composicion farmaceutica y uso para tratar la osteoartritis, artritis reumatoidea y el dolor asociado.
CL2014003167A1 (es)	2015-06-12	Molécula de unión que se une específicamente a inteleuquina 6 (il-6); composición farmacéutica que la comprende; ácido nucleico; vector; célula huésped; y uso para tratar enfermedad o trastorno asociado a il-6.
BR112013010169A2 (pt)	2016-09-13	uso de monascus na produção de ácido orgânico
BR112012015447A2 (pt)	2016-03-15	composição tópica para aplicação cutânea